Skip to main content

Core value dossiers for medical technologies

Essential tool to support market access and marketing efforts through the lifecycle of the product

Learn more
See details

Reimbursement summary for angioplasty of arteries of lower extremities

This post presents an extract from our reimbursement analysis for angioplasty of arteries lower extremities using plain and drug-coated balloons (DCBs) for peripheral artery disease in England, France and Germany. Plain balloon angioplasty is reimbursement via DRG solely and DCBs are reimbursement via combination of DRG and add-on reimbursement.
See details

HTAs in Finland in June 2024

In June 2024, the Finnish Coordinating Center for Health Technology Assessment (FinCCHTA) announced that two rapid hospital assessments in the extracorporeal treatments and endoscopy fields were accomplished:

  • Abdominal normothermic regional perfusion (A-NRP) in transplantation;
  • Endoscopic ultrasound-guided (EUS) radiofrequency ablation (RFA) treatment of pancreatic tumors.

These rapid hospital assessments were performed by the Helsinki University Hospital; however, the reports themselves are not available. 

In June 2024, the FinCCHTA also released a Digi-HTA assessment aiming to evaluate the Tunstall TSP system, which is used to receive personal alarm alerts and to forward related assistance tasks. The system includes web and desktop applications designed for professional use in processing alerts. The clients are provided with a Lifeline Digital personal alarm device through which the alerts are forwarded. In addition to the personal alarms, the system may be fitted with various sensors and accessories not included in this assessment.

According to the assessment subareas, the product received the following scores:

  • Effectiveness – promising but more evidence is needed (1);
  • Safety – sufficient (2);
  • Costs – reasonable (2);
  • Data security and data protection – sufficient (2);
  • Usability and accessibility – sufficient (2).

The product received a total score of 9 (out of 10), which means that the product meets the assessment criteria mainly and that the organization considering the deployment of this product should note that in one key area, there are things to consider. More evidence of its effectiveness is still needed. The assessment is valid until June 2027.

See the full details in Finnish herehere, and here.

This news is just one of about 300 market access news collected by our team in the premium subscription service Market Access Monitor every week from more than 80 organizations. Access our paid service to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). Access is organized as an online Database and email alert formats. Contact us to get a free, three-month, no-obligation trial.